Tonix Pharmaceuticals
TNXP
70 hedge funds and large institutions have $58.5M invested in Tonix Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 8 reducing their positions, and 7 closing their positions.
338% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 8
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
17% more funds holding
Funds holding: 60 → 70 (+10)
4.88% more ownership
Funds ownership: 26.9% → 31.78% (+4.9%)
3% more capital invested
Capital invested by funds: $57M → $58.5M (+$1.52M)
40% less call options, than puts
Call options by funds: $870K | Put options by funds: $1.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.4M |
| 2 |
BlackRock
New York
|
+$3.75M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.15M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Fund Management (CFM)
Paris,
France
|
-$1.52M |
| 2 |
SPS
Susquehanna Portfolio Strategies
Bala Cynwyd,
Pennsylvania
|
-$1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$810K |
| 4 |
Squarepoint
New York
|
-$764K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$639K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
CIBC Asset Management
Toronto,
Ontario, Canada
| – | -$424K | -17,568 | Closed |
|
|
AWP
77
Abacus Wealth Partners
Santa Monica,
California
| – | -$362K | -15,000 | Closed |
|
TNXP Hedge Fund Activity: Q4 2025 in Review
70 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q4 2025, worth a combined $58.5M — up 2.7% from $57M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TNXP positions and 7 closed out — a net gain of 10 holders — while 35 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $11.4M. The largest seller was Capital Fund Management (CFM), exiting entirely with an estimated $1.52M sold.
- 70 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q4 2025, up from 60 in Q3 2025.
- Funds reported $58.5M of Tonix Pharmaceuticals stock for Q4 2025, up 2.7% quarter-over-quarter.
- 17 funds opened new Tonix Pharmaceuticals positions in Q4 2025 and 7 closed out, a net change of +10 holders.
- The largest Tonix Pharmaceuticals buyer in Q4 2025 was Point72 Asset Management, an estimated $11.4M added.
- The largest Tonix Pharmaceuticals seller in Q4 2025 was Capital Fund Management (CFM), an estimated $1.52M sold.
Based on aggregated 13F filings for Q4 2025.